Public Views of Gene Editing for Babies Depend on How It Would Be Used
By Cary Funk and Meg Hefferon,
Pew Research Center
| 07. 26. 2018
Americans’ views on the appropriateness of changing a baby’s genetic characteristics depend in large part on the intended purpose and on whether or not human embryos would be used in testing these techniques. A majority of Americans support the idea of using gene editing with the goal of delivering direct health benefits for babies, but at the same time, a majority considers the use of such techniques to boost a baby’s intelligence something that takes technology “too far.”
About seven-in-ten Americans (72%) say that changing an unborn baby’s genetic characteristics to treat a serious disease or condition that the baby would have at birth is an appropriate use of medical technology, while 27% say this would be taking technology too far. A somewhat smaller share of Americans say gene editing to reduce a baby’s risk of developing a serious disease or condition over their lifetime is appropriate (60% say this, while 38% say it would be taking medical technology too far). But just 19% of Americans say it would be appropriate to use gene editing to make a baby more...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...